Revolutionizing Brain Health: Alloy Therapeutics to Enable Breakthrough Drug Discovery of Lundbeck’s Biologics

Alloy Therapeutics, a biotechnology ecosystem company, is proud to announce a new collaboration with Lundbeck, a global pharmaceutical powerhouse specializing in brain diseases. Together, they seek to discover novel biologics therapies that could revolutionize the way we treat brain diseases. With the combined expertise of both companies, they are confident they can make a real difference in the lives of those living with these illnesses.

Lundbeck has forged an alliance with Alloy to gain access to its innovative Antibody Discovery Services and SeqImmune™ discovery module – a sequence-first workflow for quickly and efficiently capturing early repertoires and creating maximum initial diversity.

Since 2020, Lundbeck and Alloy have been deepening their relationship through the licensing of Alloy’s ATX-Gx™ humanized transgenic mouse platform, providing Lundbeck with complementary capabilities to enhance its biologics discovery efforts. Together, the two companies are striving to make groundbreaking advancements in the field.

We are thrilled to partner with Alloy to bring our internal scientific expertise to the forefront of biologics discovery. Alloy’s innovative mindset and dedication to the success of its partners has left us impressed, and we look forward to combining our capabilities to create inspiring results.

In 2017, Alloy set out to revolutionize the way pre-competitive biologics discovery technologies and expertise are accessed, with the aim of making it easier for the global scientific community to develop better medicines together. Their ATX-Gx platform was the first step in this mission, and was soon followed by the launch of the Antibody Discovery Service, providing scientists with a comprehensive solution for outsourcing their biologics discovery needs.

At Alloy, we are dedicated to helping our partners find the best possible therapeutic antibodies for their target and providing them with a comprehensive data package to ensure optimal results.

To make the process even more successful, we offer additional value-add services such as machine-learning-driven affinity maturation and optimization, bispecific engineering, translational medicine, and advanced antibody production. With our Antibody Discovery Service, you can be sure that you are getting the best antibodies for your target.

Alloy is passionate about pushing the boundaries of innovation and is committed to reinvesting 100 percent of its revenue back into fueling progress. By doing so, they are constantly innovating and upgrading the technologies used in their discovery campaigns, making them more efficient and reliable than ever before.

Biotherapeutic Discovery at Lundbeck is devoted to restoring the brain to its optimal state. Our cutting-edge research is centred around finding antibodies and biologics that can treat brain diseases effectively. We understand the delicate nature of the brain, which is why we demand only the highest quality drug lead candidates to meet our rigorous standards.

TheATX-Gx platform, equipped with SeqImmune’s discovery module, holds the promise of uncovering highly diverse antibody repertoires, which is essential for finding the few potential drug leads. According to Allan Jensen, Vice President Biotherapeutic Discovery at Lundbeck, this capability is key for successful drug development.

Our partnership with Lundbeck is a testament to our commitment to supporting the global scientific community in their efforts to create the most effective treatments for patients. We are honored that Lundbeck has placed their trust in us and chosen to expand our collaboration by utilizing our SeqImmune antibody discovery workflow. We are proud to have been working with Lundbeck for years to develop our platform technology.

About Alloy Therapeutics

At Alloy Therapeutics, we’re committed to revolutionizing the global scientific community’s ability to make medicines that make a difference. We bring together a diverse network of academic, biotech, and pharmaceutical partners to provide access to pre-competitive resources and technologies.

Our unique Innovation Subscriptions give partners access to all current and future innovations for a flat annual fee. We reinvest 100% of our revenue in innovation and access to innovation, so everyone can benefit from the latest breakthroughs. Join us on our mission to make a lasting impact in the field of biotechnology.

About H. Lundbeck A/S

For over seven decades, H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) has been a leader in neuroscience research and solutions for brain diseases. We are passionate about restoring brain health for everyone, so that everyone can achieve their best. Our commitment to this cause is unwavering, and we strive to make a positive impact on the lives of people living with brain diseases all over the world.

At NeuroScience, we strive to create a world without stigma or discrimination against those living with brain diseases. We are dedicated to discovering and developing treatments to help make a positive impact on brain health conditions.

Our research teams are tackling some of the most challenging issues in neuroscience, while our production facilities in Denmark, France, and Italy are working to bring forward transformative treatments. With research facilities in both Denmark and the United States, we are committed to making a difference for those living with a brain disease.

Leave a Comment